Transcriptomic profiling of peripheral blood cells in <scp>HPV</scp>‐associated carcinoma patients receiving combined valproic acid and avelumab

Bozorgmehr, Najmeh; Syed, Hussain; Mashhouri, Siavash; Walker, John; Elahi, Shokrollah

doi:10.1002/1878-0261.13519

Cited by 4 publications

(2 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data were acquired on the V-plex ® Sector Imager 2400 plate reader. Analyte concentrations were extrapolated from a standard curve calculated using a four-parameter logistic fit using MSD Workbench 3.0 software according to reported protocols ( 82 – 84 ).…”

Section: Methodsmentioning

confidence: 99%

Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome

Saito,

Shahbaz,

Luo

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

IntroductionA group of SARS-CoV-2 infected individuals present lingering symptoms, defined as long COVID (LC), that may last months or years post the onset of acute disease. A portion of LC patients have symptoms similar to myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), which results in a substantial reduction in their quality of life. A better understanding of the pathophysiology of LC, in particular, ME/CFS is urgently needed.MethodsWe identified and studied metabolites and soluble biomarkers in plasma from LC individuals mainly exhibiting ME/CFS compared to age-sex-matched recovered individuals (R) without LC, acute COVID-19 patients (A), and to SARS-CoV-2 unexposed healthy individuals (HC).ResultsThrough these analyses, we identified alterations in several metabolomic pathways in LC vs other groups. Plasma metabolomics analysis showed that LC differed from the R and HC groups. Of note, the R group also exhibited a different metabolomic profile than HC. Moreover, we observed a significant elevation in the plasma pro-inflammatory biomarkers (e.g. IL-1α, IL-6, TNF-α, Flt-1, and sCD14) but the reduction in ATP in LC patients. Our results demonstrate that LC patients exhibit persistent metabolomic abnormalities 12 months after the acute COVID-19 disease. Of note, such metabolomic alterations can be observed in the R group 12 months after the acute disease. Hence, the metabolomic recovery period for infected individuals with SARS-CoV-2 might be long-lasting. In particular, we found a significant reduction in sarcosine and serine concentrations in LC patients, which was inversely correlated with depression, anxiety, and cognitive dysfunction scores.ConclusionOur study findings provide a comprehensive metabolomic knowledge base and other soluble biomarkers for a better understanding of the pathophysiology of LC and suggests sarcosine and serine supplementations might have potential therapeutic implications in LC patients. Finally, our study reveals that LC disproportionally affects females more than males, as evidenced by nearly 70% of our LC patients being female.

show abstract

Section: Methodsmentioning

confidence: 99%

Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome

Saito,

Shahbaz,

Luo

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, in the current issue of Molecular Oncology, Bozorgmehr et al [9] focused on the response of HPV-infected patients with various types of cancer to a treatment course combining epigenetic inhibitor (valproic acid) and immunotherapy (avelumab). They investigated the transcriptomic profile of Fig.…”

mentioning

confidence: 99%

Decoding HPV: disease stage and treatment insights

Yılmaz

2024

Molecular Oncology

View full text Add to dashboard Cite

An outlook of human papilloma virus (HPV) in oncogenesis and its role in therapy. The integrated HPV DNA can induce transcriptional upregulation in vicinity or transcription of oncogenes through long‐range chromatin interactions [Singh AK et al. (2023) Mol Oncol , https://doi.org/10.1002/1878-0261.13559 ] and the level of circulating cell‐free HPV DNA is related to disease severity [Bønløkke S et al. (2022) Cells , https://doi.org/10.3390/cells11142170 ]. In addition, plasma IL‐8/IL‐18 levels can be used as biomarkers for predicting therapy response in HPV‐related cancers [Bønløkke S et al. (2023) Mol Oncol , https://doi.org/10.1002/1878-0261.13538 ].

show abstract

Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model

Mashhouri,

Rahmati,

Azimi

et al. 2024

Cell Oncol.

View full text Add to dashboard Cite

Purpose Acquired resistance to immune checkpoint blockers (ICBs) is a major barrier in cancer treatment, emphasizing the need for innovative strategies. Dectin-1 (gene Clec7a) is a C-type lectin receptor best known for its ability to recognize β-glucan-rich structures in fungal cell walls. While Dectin-1 is expressed in myeloid cells and tumor cells, its significance in cancer remains the subject of controversy. Methods Using Celc7a-/- mice and curdlan administration to stimulate Dectin-1 signaling, we explored its impact. VISTA KO mice were employed to assess VISTA’s role, and bulk RNAseq analyzed curdlan effects on neutrophils. Results Our findings reveal myeloid cells as primary Dectin-1 expressing cells in the tumor microenvironment (TME), displaying an activated phenotype. Strong Dectin-1 co-expression/co-localization with VISTA and PD-L1 in TME myeloid cells was observed. While Dectin-1 deletion lacked protective effects, curdlan stimulation significantly curtailed B16-F10 tumor progression. RNAseq and pathway analyses supported curdlan’s role in triggering a cascade of events leading to increased production of pro-inflammatory mediators, potentially resulting in the recruitment and activation of immune cells. Moreover, we identified a heterogeneous subset of Dectin-1+ effector T cells in the TME. Similar to mice, human myeloid cells are the prominent cells expressing Dectin-1 in cancer patients. Conclusion Our study proposes Dectin-1 as a potential adjunctive target with ICBs, orchestrating a comprehensive engagement of innate and adaptive immune responses in melanoma. This innovative approach holds promise for overcoming acquired resistance to ICBs in cancer treatment, offering avenues for further exploration and development.

show abstract

Transcriptomic profiling of peripheral blood cells in HPV‐associated carcinoma patients receiving combined valproic acid and avelumab

Cited by 4 publications

References 107 publications

Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome

Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome

Decoding HPV: disease stage and treatment insights

Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model

Contact Info

Product

Resources

About